Animal Model:	NMDA Receptor Antagonist Rx (MK801, PCP, Ketamine)-Acute
Preparation Type:	Drug-Induced Preparations
DA-related behavior:	Increases locomotor activity and stereotopy, ataxia
Gating:	Disrupted PPI 1 day after PCP, and 15 minutes after PCP, but not 7 or 28 days later, abnormal latent inhibition
Cognitive behavior:	Decreased working memory, disrupted fear conditioning, long-term spatial memory deficits, impaired passive-avoidance, recognition memory deficit
Social behavior:	Impaired social interaction
Molecular/morphological signature:	Impaired LTP, decreased AMPA receptor density
Response to APD:	Enhanced locomotor responses blocked by APD, glycine transporter-1 inhibition rescues LTP, PPI disruption attenuated by admatine, glycine, D-serine, not D-cycloserine, fear conditioning disruption prevented by clozapine, but not haloperidol, LI abnormalities reversed by risperidone and M100907, passive avoidance impairment reversed by lurasidone, recognition memory deficit reversed by clozapine and D-serine, but not haloperidol